Advertisement
Screener

Neurogene Inc. (NGNE) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Neurogene Inc. Operating Cash Flow

Neurogene Inc. (NGNE) reported Operating Cash Flow of -$49.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11

  • Neurogene Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$23.76M.
  • Neurogene Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$26.12M.
  • Neurogene Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.43M.
  • Neurogene Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$19.51M.
  • Neurogene Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$77.17M.
  • Neurogene Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$70.60M.
  • Neurogene Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$51.42M.
  • Neurogene Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$52.82M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$23.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$49.88M
10-Q · filed 2026-08-11
-$67.31M
derived: sum of 3 quarters · filed 2026-08-11
-$86.82M
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31-$26.12M
10-Q · filed 2026-05-12
-$43.55M
derived: sum of 2 quarters · filed 2026-05-12
-$63.06M
derived: sum of 3 quarters · filed 2026-05-12
-$82.52M
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31-$17.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$36.94M
derived: sum of 2 quarters · filed 2026-03-24
-$56.40M
derived: sum of 3 quarters · filed 2026-08-11
-$77.17M
10-K · filed 2026-03-24
2025-09-30-$19.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$38.97M
derived: sum of 2 quarters · filed 2026-08-11
-$59.74M
10-Q · filed 2025-11-13
-$77.24M
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30-$19.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$40.24M
10-Q · filed 2026-08-11
-$57.73M
derived: sum of 3 quarters · filed 2026-08-11
-$73.30M
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31-$20.77M
10-Q · filed 2026-05-12
-$38.27M
derived: sum of 2 quarters · filed 2026-05-12
-$53.83M
derived: sum of 3 quarters · filed 2026-05-12
-$69.73M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$17.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
-$33.06M
derived: sum of 2 quarters · filed 2026-03-24
-$48.95M
derived: sum of 3 quarters · filed 2026-03-24
-$70.60M
10-K · filed 2026-03-24
2024-09-30-$15.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$31.46M
derived: sum of 2 quarters · filed 2025-11-13
-$53.11M
10-Q · filed 2025-11-13
-$70.08M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$15.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
-$37.54M
10-Q · filed 2025-08-11
-$54.52M
derived: sum of 3 quarters · filed 2025-08-11
-$66.08M
derived: sum of 4 quarters · filed 2025-08-11
2024-03-31-$21.65M
10-Q · filed 2025-05-09
-$38.62M
derived: sum of 2 quarters · filed 2025-05-09
-$50.19M
derived: sum of 3 quarters · filed 2025-05-09
-$59.52M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31-$16.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
-$28.54M
derived: sum of 2 quarters · filed 2025-03-24
-$37.87M
derived: sum of 3 quarters · filed 2025-03-24
-$51.42M
10-K · filed 2025-03-24
2023-09-30-$11.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18
-$20.89M
derived: sum of 2 quarters · filed 2024-11-18
-$34.45M
10-Q · filed 2024-11-18
-$21.35M
10-Q · filed 2023-11-14
-$52.60M
derived: sum of 4 quarters · filed 2024-11-18
2023-06-30-$9.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
-$22.88M
10-Q · filed 2024-08-09
-$17.08M
10-Q · filed 2023-08-10
-$41.03M
derived: sum of 3 quarters · filed 2024-08-09
-$50.32M
derived: sum of 4 quarters · filed 2024-08-09
2023-03-31-$13.55M
10-Q · filed 2024-05-10
-$13.03M
10-Q · filed 2023-05-08
-$31.70M
derived: sum of 2 quarters · filed 2024-05-10
-$40.99M
derived: sum of 3 quarters · filed 2024-05-10
-$52.29M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31-$18.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
-$27.44M
derived: sum of 2 quarters · filed 2024-03-18
-$38.73M
derived: sum of 3 quarters · filed 2024-03-18
-$52.82M
10-K · filed 2024-03-18
-$45.61M
10-K · filed 2023-03-20
2022-09-30-$9.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$20.58M
derived: sum of 2 quarters · filed 2023-11-14
-$34.67M
10-Q · filed 2023-11-14
-$46.84M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$11.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$25.39M
10-Q · filed 2023-08-10
-$37.55M
derived: sum of 3 quarters · filed 2023-08-10
-$46.31M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$14.09M
10-Q · filed 2023-05-08
-$26.26M
derived: sum of 2 quarters · filed 2023-05-08
-$35.02M
derived: sum of 3 quarters · filed 2023-05-08
-$48.29M
derived: sum of 4 quarters · filed 2023-05-08
2021-12-31-$12.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
-$20.92M
derived: sum of 2 quarters · filed 2023-03-20
-$34.20M
derived: sum of 3 quarters · filed 2023-03-20
-$47.56M
10-K · filed 2023-03-20
2021-09-30-$8.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$22.03M
derived: sum of 2 quarters · filed 2022-11-14
-$35.39M
10-Q · filed 2022-11-14
-$44.62M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$13.28M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$26.63M
10-Q · filed 2022-08-09
-$35.86M
derived: sum of 3 quarters · filed 2022-08-09
-$35.98M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$13.36M
10-Q · filed 2022-05-09
-$22.59M
derived: sum of 2 quarters · filed 2022-05-09
-$22.70M
derived: sum of 3 quarters · filed 2022-05-09
-$31.49M
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31-$9.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$9.34M
derived: sum of 2 quarters · filed 2022-03-01
-$18.14M
derived: sum of 3 quarters · filed 2022-03-01
-$24.57M
10-K · filed 2022-03-01
2020-09-30-$112.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$8.91M
derived: sum of 2 quarters · filed 2021-11-04
-$15.35M
10-Q · filed 2021-11-04
-$19.98M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$8.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$15.23M
10-Q · filed 2021-08-05
-$19.87M
derived: sum of 3 quarters · filed 2021-08-05
-$26.40M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$6.44M
10-Q · filed 2021-05-12
-$11.08M
derived: sum of 2 quarters · filed 2021-05-12
-$17.61M
derived: sum of 3 quarters · filed 2021-05-12
-$19.08M
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31-$4.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
-$11.17M
derived: sum of 2 quarters · filed 2021-03-25
-$12.64M
derived: sum of 3 quarters · filed 2021-03-25
-$15.39M
10-K · filed 2021-03-25
2019-09-30-$6.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$8.00M
derived: sum of 2 quarters · filed 2020-11-09
-$10.76M
10-Q · filed 2020-11-09
-$20.53M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30-$1.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
-$4.23M
10-Q · filed 2020-08-12
-$14.00M
derived: sum of 3 quarters · filed 2020-08-12
-$29.39M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31-$2.76M
10-Q · filed 2020-05-06
-$12.53M
derived: sum of 2 quarters · filed 2020-05-06
-$27.93M
derived: sum of 3 quarters · filed 2020-05-06
-$18.74M
derived: sum of 4 quarters · filed 2020-05-06
2018-12-31-$9.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$25.17M
derived: sum of 2 quarters · filed 2020-03-12
-$15.99M
derived: sum of 3 quarters · filed 2020-03-12
-$31.58M
10-K · filed 2020-03-12
2018-09-30-$15.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13
-$6.21M
derived: sum of 2 quarters · filed 2019-11-13
-$21.80M
10-Q · filed 2019-11-13
-$33.41M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$9.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
-$6.41M
10-Q · filed 2019-08-01
-$18.01M
derived: sum of 3 quarters · filed 2020-03-12
-$29.54M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31-$15.59M
10-Q · filed 2019-05-07
-$27.19M
derived: sum of 2 quarters · filed 2020-03-12
-$38.72M
derived: sum of 3 quarters · filed 2020-03-12
-$49.03M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31-$11.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$23.14M
derived: sum of 2 quarters · filed 2020-03-12
-$33.44M
derived: sum of 3 quarters · filed 2020-03-12
-$44.72M
10-K · filed 2020-03-12
2017-09-30-$11.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
-$21.83M
derived: sum of 2 quarters · filed 2018-11-07
-$33.11M
10-Q · filed 2018-11-07
2017-06-30-$10.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$21.58M
10-Q · filed 2018-08-08
2017-03-31-$11.28M
10-Q · filed 2018-05-08
2016-12-31-$30.23M
10-K · filed 2019-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76